The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Celgene Corporation Announces Appointment of Thomas M. Moriarty as General Counsel

Monday, May 07, 2012

Celgene Corporation Announces Appointment of Thomas M. Moriarty as General Counsel07:30 EDT Monday, May 07, 2012 SUMMIT, N.J. (Business Wire) -- Celgene Corporation (NASDAQ: CELG) today announced the appointment of Thomas M. Moriarty as General Counsel and Corporate Secretary. In this position, he will be responsible for global legal strategy at Celgene and will serve on the company's Management Committee. Mr. Moriarty joins Celgene from Medco Health Solutions where he directed all legal, regulatory, public policy and corporate governance functions as General Counsel and Corporate Secretary since 2008. He also served as President, Global Pharmaceutical Strategies, Senior Vice President, Pharma Strategies & Solutions and Senior Vice President of Business Development since joining Medco Health Solutions in June 2000. Prior to joining Medco, Mr. Moriarty held a number of leadership positions in the biopharmaceutical industry including Assistant General Counsel – Pharma & North America for Merial Limited, a Merck & Co. and Aventis Company, and previously as Senior Attorney for Merck & Co. “Tom Moriarty brings a wealth of experience in global strategic and legal healthcare management,” said Robert J. Hugin, Chairman and CEO of Celgene Corporation. “His extensive legal background, as well as his significant leadership experience will provide new insight and valuable perspective on the increasingly complex global healthcare environment.” Mr. Moriarty received his J.D. from the University of Virginia School of Law and a bachelor's degree in government and law from Lafayette College. About Celgene Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com. Forward-Looking StatementsThis press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.For Celgene:Investors:908-673-9628investors@celgene.comorMedia:908-673-2275media@celgene.com